Articles > technology
The COVID-19 pandemic has put immense pressure on both individuals with T1D, and the organizations who provide them with vital supplies and medications. While there’s no doubt that people with T1D face a more uncertain and risk-filled future as we navigate quarantine and social distancing, there have been some promising steps from several sides that have …
Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.
Almost three months ago, I joined the T1D Exchange team as a clinical research manager. I continue to be impressed with the passion and level of commitment among my colleagues to improve the lives of people with type 1 diabetes (T1D). Recently, our team has been working on an important campaign to #SmashDiabetes. When the […]
On December 2, 2013, The Type 1 Diabetes Program of The Leona M. and Harry B. Helmsley Charitable Trust announced its Automated Insulin Delivery Initiative (AIDI), through which it will provide up to $30 million in grants over the next three years to accelerate the development and regulatory approval of new technologies that will automatically […]
My name is Chester Lynn Wickwire (I go by my middle name) and have lived with type 1 diabetes for 68 years, diagnosed in October 1944, at four and a half at the Yale New Haven Hospital. I am now 72, married, with a son and a daughter and two granddaughters, none of whom have […]